Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
Eur Heart J. 2016-06-29; 37(38): 2882-2889
DOI: 10.1093/EURHEARTJ/EHW233
Read on PubMed
1. Eur Heart J. 2016 Oct 7;37(38):2882-2889. Epub 2016 Jun 29.
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results
from GARFIELD-AF.
Bassand JP(1)(2), Accetta G(2), Camm AJ(3), Cools F(4), Fitzmaurice DA(5), Fox
KA(6), Goldhaber SZ(7), Goto S(8), Haas S(9), Hacke W(10), Kayani G(2), Mantovani
LG(11), Misselwitz F(12), Ten Cate H(13), Turpie AG(14), Verheugt FW(15)(16),
Kakkar AK(2)(17); GARFIELD-AF Investigators.
Author information:
(1)University of Besançon, Besançon, France
.
(2)Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London
SW3 6LR, UK.
(3)St George’s University of London, London, UK.
(4)AZ Klina, Brasschaat, Belgium.
(5)University of Birmingham, Edgbaston, Birmingham, UK.
(6)University of Edinburgh, Edinburgh, UK.
(7)Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA.
(8)Tokai University, Kanagawa, Japan.
(9)Formerly Technical University of Munich, Munich, Germany.
(10)University of Heidelberg, Heidelberg, Germany.
(11)University of Milano-Bicocca, Milan, Italy.
(12)Bayer HealthCare Pharmaceuticals, Berlin, Germany.
(13)Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
(14)McMaster University, Hamilton, Canada.
(15)University Hospital, Nijmegen.
(16)Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
(17)University College London, London, UK.
Comment in
Eur Heart J. 2016 Oct 7;37(38):2890-2892.
AIMS: The relationship between outcomes and time after diagnosis for patients
with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond
the first year.
METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of
adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients
prospectively enrolled in GARFIELD-AF were analysed in light of baseline
characteristics, risk profiles for stroke/systemic embolism (SE), and
antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years,
43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of
patients were prescribed anticoagulant therapy with/without antiplatelet (AP)
therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year
follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a
rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70
(0.62; 0.81) per 100 person-years, respectively. Rates for all three major events
were highest during the first 4 months. Congestive heart failure, acute coronary
syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and
infection/sepsis accounted for 65% of all known causes of death and strokes for